ATE365209T1 - Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie - Google Patents

Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie

Info

Publication number
ATE365209T1
ATE365209T1 AT93911198T AT93911198T ATE365209T1 AT E365209 T1 ATE365209 T1 AT E365209T1 AT 93911198 T AT93911198 T AT 93911198T AT 93911198 T AT93911198 T AT 93911198T AT E365209 T1 ATE365209 T1 AT E365209T1
Authority
AT
Austria
Prior art keywords
steroid hormone
methods
molecular switch
present
provides
Prior art date
Application number
AT93911198T
Other languages
English (en)
Inventor
Elisabetta Vegeto
Donald Mcdonnell
Bert O'malley
William Schrader
Ming-Jer Tsai
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/882,771 external-priority patent/US5364791A/en
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE365209T1 publication Critical patent/ATE365209T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8237—Externally regulated expression systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8237—Externally regulated expression systems
    • C12N15/8238—Externally regulated expression systems chemically inducible, e.g. tetracycline
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93911198T 1992-05-14 1993-05-11 Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie ATE365209T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/882,771 US5364791A (en) 1992-05-14 1992-05-14 Progesterone receptor having C. terminal hormone binding domain truncations
US93924692A 1992-09-02 1992-09-02

Publications (1)

Publication Number Publication Date
ATE365209T1 true ATE365209T1 (de) 2007-07-15

Family

ID=27128671

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93911198T ATE365209T1 (de) 1992-05-14 1993-05-11 Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie

Country Status (8)

Country Link
US (3) US5935934A (de)
EP (1) EP0745121B1 (de)
JP (1) JPH07509694A (de)
AT (1) ATE365209T1 (de)
AU (1) AU685054C (de)
CA (1) CA2135644C (de)
DE (1) DE69334150T2 (de)
WO (1) WO1993023431A1 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416998B1 (en) * 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
ATE365209T1 (de) * 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5789156A (en) * 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5654168A (en) * 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
EP0705334A1 (de) * 1993-06-14 1996-04-10 Basf Aktiengesellschaft Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren
US6004941A (en) * 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
US5814618A (en) * 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5859310A (en) 1993-06-14 1999-01-12 Basf Aktiengesellschaft Mice transgenic for a tetracycline-controlled transcriptional activator
US5888981A (en) * 1993-06-14 1999-03-30 Basf Aktiengesellschaft Methods for regulating gene expression
US5912411A (en) * 1993-06-14 1999-06-15 University Of Heidelberg Mice transgenic for a tetracycline-inducible transcriptional activator
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
EP0743520A3 (de) * 1993-12-30 1999-11-10 The Salk Institute For Biological Studies Neue Verwendungen von Gal4-Rezeptor-Konstruktionen
US5853717A (en) 1994-07-20 1998-12-29 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5935849A (en) * 1994-07-20 1999-08-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
AU703124B2 (en) * 1995-03-03 1999-03-18 Syngenta Participations Ag Control of gene expression in plants by receptor mediated transactivation in the presence of a chemical ligand
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6495364B2 (en) * 1995-05-23 2002-12-17 Neurotech, S.A. Mx-1 conditionally immortalized cells
CN1191568A (zh) 1995-05-26 1998-08-26 曾尼卡有限公司 包含蜕皮激素受体的基因开关
EP0871729A1 (de) * 1995-09-15 1998-10-21 Baylor College Of Medicine Zusammensetzungen mit koaktivatorwirkung auf steroidrezeptoren und methoden fürihre verwendung
AU7074496A (en) 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
EP0859851A1 (de) * 1995-10-10 1998-08-26 Novartis AG Juvenilhormon oder einer seiner agonisten als chemischer ligand für die kontrolle der pflanzengenexpression durch rezeptorvermittelte transaktivation
US6610828B1 (en) 1996-05-24 2003-08-26 Syngenta Limited Heliothis ecdysone receptor
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
ATE371736T1 (de) * 1996-10-29 2007-09-15 Baylor College Medicine Modifizierte steroid-hormon rezeptoren
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
AU4845297A (en) * 1997-06-20 1998-12-24 Case Western Reserve University Expression system for production of therapeutic proteins
CA2297375A1 (en) 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
AU753926B2 (en) * 1998-03-20 2002-10-31 Genzyme Corporation Novel complementing receptor-ligand pairs and adoptive immunotherapy using same
US6475733B1 (en) * 1998-04-06 2002-11-05 Lerner Pharmaceuticals, Inc. Cell surface receptors for the detection and identification of compounds
EP1093362A1 (de) 1998-06-12 2001-04-25 Ligand Pharmaceuticals Incorporated Verwendung von rxr modulatoren zur behandlung von anti-östrogen-resistent brustkrebs
WO2000015791A1 (en) 1998-09-10 2000-03-23 Pioneer Hi-Bred International, Inc. Ecdysone receptors and methods for their use
JP2002537311A (ja) * 1999-02-19 2002-11-05 オクタジーン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ホルモン−ホルモン受容体の複合体および核酸構築物、並びに遺伝子治療におけるそれらの使用
EP1165808A2 (de) * 1999-03-03 2002-01-02 Genelabs Technologies, Inc. Durch dns-bindende verbindungen regulierter molekularer schalter
US7189506B1 (en) 1999-03-03 2007-03-13 Genelabs Technologies, Inc. DNA binding compound-mediated molecular switch system
CA2369855A1 (en) * 1999-05-28 2001-01-04 Sangamo Biosciences, Inc. Molecular switches
DE60023261T2 (de) * 1999-07-23 2006-07-27 Olympus Corporation Verfahren zur untersuchung der wechselwirkung von substanz und hormonrezeptor
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
DE19958159A1 (de) * 1999-12-02 2001-06-07 Degussa Neue für das glk-Gen codierende Nukleotidsequenzen
DK1254169T3 (da) 1999-12-30 2007-08-06 Harvard College Fremgangsmåde vedrörende modulering af aktivitet af Th2-celledelmængde ved modulering af aktivitet af XBP-1
EP1741445B1 (de) 2000-01-21 2013-08-14 Novartis AG Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
WO2001053479A2 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Molecular switches ii
US7132277B1 (en) 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
US7335646B2 (en) 2000-03-13 2008-02-26 Engene, Inc. Compositions and methods for regulated protein expression in gut
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
US7011972B2 (en) * 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
ATE428790T1 (de) * 2000-09-25 2009-05-15 Genetronics Inc Verbessertes system zur regulation der transgenexpression
AU2002253836A1 (en) * 2000-10-20 2002-08-19 Canji, Inc Aptamer-mediated regulation of gene expression
AU2002243280A1 (en) * 2000-10-23 2002-06-24 Engeneos, Inc. Engineered stimulus-responsive switches
JP2004533212A (ja) 2000-10-24 2004-11-04 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 植物における遺伝子発現のコントロール
JP2004533226A (ja) 2001-04-02 2004-11-04 ワイス Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用
EP1397382B1 (de) 2001-05-31 2008-08-06 Novartis AG Neue östrogenrezeptorligandenbindungsdomänen varianten und neue liganden und pharmazeutische zusammensetzungen
US20020197670A1 (en) * 2001-06-22 2002-12-26 Price Thomas M. Membrane associated progesterone receptor
KR100460478B1 (ko) * 2001-08-13 2004-12-08 김경섭 신규한 ｄｎａ 결합 단백질 및 이를 이용한 유전자 발현시스템
CA2464199C (en) 2001-10-26 2013-12-24 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject
MY142457A (en) 2001-12-11 2010-11-30 Advisys Inc Plasmid mediated supplementation for treating chronically ill subjects
EP1388352A1 (de) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
US20060019964A1 (en) * 2002-10-16 2006-01-26 Ancliff Ranchael A Compounds
ATE441417T1 (de) * 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
WO2004074473A1 (ja) * 2003-01-29 2004-09-02 Toyo Boseki Kabushiki Kaisha 変異型レセプター及びその製造方法並びに変異型レセプターと正常型レセプターを用いるリガンドの分別評価方法、スクリーニング方法およびそのためのキット
WO2004085611A2 (en) * 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
US20060293298A1 (en) * 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
DE602004015269D1 (de) * 2003-04-23 2008-09-04 Glaxo Group Ltd Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
CA2539439C (en) 2003-09-19 2012-10-23 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0405628D0 (en) * 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
GB0408083D0 (en) * 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
WO2005113015A1 (en) * 2004-05-24 2005-12-01 Niklas Arnberg Enhanced gene delivery using viral vectors
PE20060302A1 (es) * 2004-06-18 2006-04-08 Glaxo Group Ltd Derivados de benzazepina como antagonistas del receptor h3
US8097431B2 (en) * 2004-08-04 2012-01-17 University Of Utah Research Foundation Methods and compositions for detecting steroids
US20060040298A1 (en) * 2004-08-05 2006-02-23 Azriel Schmidt Rhesus monkey NURR1 nuclear receptor
EP1982997B1 (de) 2004-09-01 2012-08-08 Allergan, Inc. Abbaubare Clostridientoxine
AU2005287278B2 (en) * 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
US7935788B2 (en) * 2004-10-04 2011-05-03 National Research Council Of Canada Reverse cumate repressor mutant
CA2580515C (en) * 2004-10-04 2017-05-02 National Research Council Of Canada Expression system, components thereof and methods of use
US7846720B2 (en) * 2005-01-26 2010-12-07 Vgx Pharmaceuticals, Inc. Optimized high yield synthetic plasmids
CA2601592A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
WO2008036060A2 (en) 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
EP1891224A1 (de) * 2005-05-19 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Interferon-beta-gentherapie unter verwendung eines verbesserten, regulierten expressionssystems
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
WO2006122971A2 (en) * 2005-05-19 2006-11-23 Bayer Schering Pharma Aktiengesellschaft Treatment of disease using an improved regulated expression system
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP2377881B1 (de) 2005-09-19 2017-04-26 Allergan, Inc. Mit Clostridientoxin aktivierbare Clostridientoxine
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
US8846102B2 (en) * 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
WO2009114748A1 (en) 2008-03-14 2009-09-17 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
BRPI1008940A2 (pt) 2009-03-13 2020-10-27 Allergan, Inc. linhagem de célula clonal estabelecida suscetível à intoxicação por bont/a
SI3281953T1 (sl) 2009-03-13 2020-03-31 Allergan, Inc. Na imunosti temelječi testi za aktivnosti ponovno ciljane endopeptidaze
EP2482849B1 (de) 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Kombinationsimmuntherapie zur krebsbehandlung
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
MX2012006985A (es) 2009-12-16 2012-09-12 Allergan Inc Toxinas clostridium modificadas que comprenden un dominio de enlace al sitio de escision de la proteasa integrado.
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
NZ601472A (en) 2010-01-25 2013-08-30 Allergan Inc Methods of intracellular conversion of single-chain proteins into their di-chain form
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
JP6148979B2 (ja) 2010-05-20 2017-06-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 分解性クロストリジウム毒素
WO2012051301A1 (en) 2010-10-12 2012-04-19 President And Fellows Of Harvard College Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
WO2015048331A1 (en) 2013-09-25 2015-04-02 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
PT3049473T (pt) 2013-09-25 2021-12-21 Engene Inc Nanopartículas de quitosana duplamente derivada e métodos de produção e utilização das mesmas para transferência de genes in vivo
KR20170109582A (ko) 2015-02-06 2017-09-29 히트 바이오로직스, 인코퍼레이티드 벡터 공동 발현 백신 및 공동 자극 분자
US10183060B2 (en) 2015-10-01 2019-01-22 Heat Biologics, Inc. Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
CN110520534A (zh) 2016-11-09 2019-11-29 恩根尼公司 程序性死亡配体1的肠表达
CN118184797A (zh) 2017-02-27 2024-06-14 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
CN112351991A (zh) 2017-12-20 2021-02-09 阿勒根公司 肉毒杆菌毒素细胞结合结构域多肽及其用于治疗纤维化相关障碍的方法
WO2020047328A1 (en) 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
US20240279336A1 (en) 2021-07-30 2024-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric proteins and methods of immunotherapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
AU633045B2 (en) 1988-12-23 1993-01-21 Salk Institute For Biological Studies, The Receptor transcription-repression activity compositions and methods
CA2057049A1 (en) * 1989-05-26 1990-11-27 Ronald M. Evans Dominant negative members of the steroid/thyroid superfamily of receptors
AU637446B2 (en) * 1990-01-16 1993-05-27 Baylor College Of Medicine Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE69123241T2 (de) * 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5215916A (en) 1991-06-19 1993-06-01 The United States Of America As Represented By The Department Of Health & Human Services Super glucocorticoid receptors: receptors with increased affinity and specificity for glucocorticoid steriods
EP0609240B1 (de) * 1991-09-17 2002-04-03 The Salk Institute For Biological Studies Rezeptoren der steroid/thyroid superfamilie von rezeptoren
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
CA2131620A1 (en) * 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
EP0577932A3 (de) * 1992-05-08 1995-04-19 American Cyanamid Co Entwicklung von einem "Screening" für den Nachweis von androgenen Rezeptorenagonisten und Antagonisten.
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
ATE365209T1 (de) * 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
JP3913309B2 (ja) * 1997-03-07 2007-05-09 Ｓｕｍｃｏ Ｔｅｃｈｘｉｖ株式会社 半導体単結晶製造方法および単結晶引上装置の整流筒の装着用治具

Also Published As

Publication number Publication date
US5874534A (en) 1999-02-23
EP0745121B1 (de) 2007-06-20
CA2135644C (en) 2009-01-27
EP0745121A4 (de) 1996-08-20
CA2135644A1 (en) 1993-11-25
EP0745121A1 (de) 1996-12-04
JPH07509694A (ja) 1995-10-26
DE69334150T2 (de) 2008-03-13
US6599698B1 (en) 2003-07-29
AU685054C (en) 2003-02-27
AU4241793A (en) 1993-12-13
DE69334150D1 (de) 2007-08-02
AU685054B2 (en) 1998-01-15
US5935934A (en) 1999-08-10
WO1993023431A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
ATE365209T1 (de) Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
ATE371736T1 (de) Modifizierte steroid-hormon rezeptoren
DE69133135D1 (de) Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes
DE69414398D1 (de) Heterocyclische neurokinin-antagonisten
ATE480252T1 (de) Peptidantagonist von zonulin und dessen verwendung
BG102124A (en) Genetic reswitching with the participation of the ecdysone receptor
MY109045A (en) Mammalian receptors for interleukin 10 (il-10)
YU35099A (sh) Korišćenje antagonista centralnog kanabinoidnog receptora za regulisanje sklonosti
DE69333594D1 (de) Für menschliche alpha-1-adrenerge rezeptoren kodierende dns und ihre verwendung
DK0760857T3 (da) Receptor for onkostatin M
NO922457D0 (no) Antistoffantagonister av humant interleukin-4
AU9135691A (en) G protein-coupled glutamate receptors
FR2514504B1 (fr) Agencement d'apport d'echantillons
Khong et al. Expression of functional melanocortin-4 receptor in the hypothalamic GT1-1 cell line
ATE299935T1 (de) Für polykationen sensitiver rezeptor von aquatischen lebewesen und methoden für seine verwendung.
ES2112340T3 (es) Proteinas mutantes de il-4 humana.
Hoegen et al. Internalization of interleukin 1 (IL 1) correlates with IL 1‐induced IL 2 receptor expression and IL 2 secretion of EL4 thymoma cells
DE69333660D1 (de) Pct-65 serotonin rezeptor
Hochman et al. Hepatocyte nuclear factor-1α regulates transcription of the guanylin gene
Haring et al. Species differences determine azido phencyclidine labeling pattern in desensitized nicotinic acetylcholine receptors
NO960715D0 (no) Fremgangsmåter for sceening av anti-östrogen forbindelser
Diamond et al. Lineage-specific expression of a T cell receptor variable gene promoter controlled by upstream sequences.
ITMI922854A0 (it) Nuovo uso degli antagonisti dei recettori 5-ht3
ATE294861T1 (de) Polypeptide mit opioider rezeptor-aktvität, für sie kodierende nukleinsäuren und ihre verwendungen
SE9700566D0 (sv) Modified proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties